FIELD: pharmacology.
SUBSTANCE: protatran 4-chloro-2-methylphenoxyacetate (chlorocresacin) is proposed as an agent that inhibits mononuclear cells basic (alkaline) phospholipase a2 total activity.
EFFECT: invention allows to expand the field of substance application and create new pharmacological preparations based on chlorocresacin to prevent sclerotic lesions of blood vessels.
2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF 1-(HERMATRANE-1-YL)-1-OXYETHYLAMINE FOR INHIBITING TOTAL ACTIVITY OF BASIC (ALKALINE) PHOSPHOLIPASE A2 OF MONONUCLEAR CELLS | 2020 |
|
RU2732883C1 |
| METHOD FOR SUPPRESSING TOTAL ACTIVITY OF BASIC (ALKALINE) PHOSPHOLIPASE A2 OF MONONUCLEAR CELLS USING 1-(HERMATRANE-1-YL)-1-OXYETHYLAMINE | 2020 |
|
RU2732881C1 |
| USE OF BIS(Μ-TARTRATO)DI(Μ-HYDROXO)GERMANATE (IV) TRIETHANOLAMMONIUM FOR INHIBITING TOTAL ACTIVITY OF BASIC (ALKALINE) PHOSPHOLIPASE A2 OF MONONUCLEAR CELLS | 2020 |
|
RU2733166C1 |
| METHOD OF INHIBITING TOTAL ACTIVITY OF BASIC (ALKALINE) PHOSPHOLIPASE A2 OF MONONUCLEAR CELLS USING BIS(Μ-TARTRATO)DI(Μ-HYDROXO)GERMANATE (IV) TRIETHANOLAMMONIUM | 2020 |
|
RU2732880C1 |
| USING COMPLEX OF TRIS-(2-HYDROXYETHYL)AMINE AND ZINC BIS-(2-METHYLPHENOXYACETATE) (CINKATRAN) AS AGENT SUPPRESSING TOTAL ACTIVITY OF BASIC (ALKALINE) MONONUCLEAR PHOSPHOLIPASE A2 | 2014 |
|
RU2546537C1 |
| USING PROTATRAN 4-CHLOR-2-METHYLPHENOXYACETATE (CHLORCRESACIN) FOR ARREST OF CHOLESTEROLESTERASE ACTIVITY | 2014 |
|
RU2563831C1 |
| USE OF 1-(GERMATRAN-1-YL)-1-HYDROXYETHYLAMINE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2746321C1 |
| METHOD OF ATHEROGENESIS CORRECTION IN EXPERIMENT USING 1-(GERMATRAN-1-YL)-1-OXYETHYLAMINE | 2020 |
|
RU2741906C1 |
| METHOD FOR CORRECTING ATHEROGENESIS EXPERIMENTALLY USING 1-HYDROXYGERMATRANE | 2020 |
|
RU2741229C1 |
| USING COMPLEX OF TRIS-(2-HYDROXYETHYL)AMINE AND BIS-(2-METHYLPHENOXY-ACETATE) ZINC (ZINCATRAN) FOR REDUCING TOTAL ACTIVITY OF ACIDIC PHOSPHOLIPASE A1 | 2014 |
|
RU2545888C1 |
